此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Intratumoral Macrophage Exosomes With Mechanobiological Reprogramming for Advanced Solid Tumors

2026年5月6日 更新者:Xingchen Peng、West China Hospital

A Phase I, Open-Label, Dose-Escalation Clinical Study to Evaluate the Safety and Tolerability of Intratumoral Administration of Macrophage-Derived Exosomes With Cellular Mechanobiological Reprogramming in Patients With Advanced Solid Tumors

The goal of this phase I clinical trial is to evaluate the safety and tolerability of intratumoral injection of mechanically reprogrammed macrophage-derived exosomes (MRMEs) in adults aged 18-65 years with advanced solid tumors who have failed, are ineligible for, or are intolerant of standard therapies.

研究概览

研究类型

介入性

注册 (估计的)

9

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Xingchen Peng
  • 电话号码:18980606753
  • 邮箱:pxx2014@163.com

学习地点

    • Sichuan
      • Chengdu、Sichuan、中国、610041
        • 招聘中
        • West China Hospital, Sichuan University

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  1. Age 18 to 65 years (inclusive) at screening, any gender.
  2. Histologically or cytologically confirmed advanced (unresectable or metastatic) solid tumors (including melanoma, soft tissue sarcoma, head and neck squamous cell carcinoma, etc.) that have failed standard therapy, have no standard treatment options, or are intolerant to standard treatment.
  3. Must have a primary lesion suitable for local injection, accessible by direct palpation or under ultrasound/CT image guidance.
  4. At least one measurable lesion per RECIST v1.1 criteria.
  5. ECOG performance status score of 0-2.
  6. Expected survival ≥ 3 months.
  7. Adequate organ function within 7 days prior to treatment:

    • Neutrophil count (NEUT#) ≥ 1.5×10^9/L; Platelets (PLT) ≥ 80×10^9/L; Hemoglobin ≥ 8 g/dL
    • AST, ALT, ALP ≤ 2.5×ULN; Total bilirubin (TBIL) ≤ 1.5×ULN; Albumin ≥ 2.8 g/dL
    • Serum creatinine ≤ 1.5×ULN or CCR > 60 ml/min
    • INR ≤ 1.5; APTT ≤ 1.5×ULN
  8. Voluntarily participates, signs informed consent, and is able to comply with study visits and procedures.

Exclusion Criteria:

  1. Contraindications to intratumoral injection: inflammation or ulceration at injection site; severe bleeding tendency; abnormal or permanent body art (e.g., tattoos) at injection site interfering with local reaction observation.
  2. History of other malignancies (except cured basal cell carcinoma, squamous cell carcinoma of skin, superficial bladder cancer, cervical carcinoma in situ, intramucosal gastrointestinal cancer without recurrence for 5 years).
  3. Active autoimmune disease or history of autoimmune disease (including but not limited to immune-related neuropathy, multiple sclerosis, autoimmune neuropathy, Guillain-Barré syndrome, myasthenia gravis, SLE, connective tissue disease, scleroderma, IBD, autoimmune hepatitis, TEN, or Stevens-Johnson syndrome); except Type 1 diabetes on stable insulin dose.
  4. Anti-tumor vaccine within 4 weeks before first dose; live vaccines within 4 weeks before or during the study; major surgery or severe trauma within 4 weeks before first dose.
  5. Prior anti-tumor treatment toxicity not recovered to ≤ CTCAE v5.0 Grade 1.
  6. Serious medical conditions: NYHA Class II or higher heart dysfunction, ischemic heart disease, significant arrhythmia, poorly controlled diabetes (fasting glucose ≥ 10 mmol/L), uncontrolled hypertension (SBP > 150 mmHg and/or DBP > 100 mmHg), LVEF < 50%, QTc > 450 ms (male) or > 470 ms (female).
  7. Active tuberculosis or uncontrolled prior TB infection.
  8. Hyperthyroidism or organic thyroid disease (except hypothyroidism controlled with stable thyroid hormone replacement).
  9. Active infection or unexplained fever within 48 hours before first dose, or systemic antibiotics within 1 week before informed consent.
  10. Active HBV (HBV DNA ≥ 2000 IU/ml or 10^4 copies/ml), active HCV (HCV antibody positive and HCV RNA above detection limit), or known HIV positive or AIDS history.
  11. Known neurological or psychiatric disorders (e.g., epilepsy, dementia).
  12. Known history of drug abuse or alcohol abuse within 3 months.
  13. Pregnant or breastfeeding women; participants (or their partners) planning pregnancy or unwilling to use contraception from screening to 6 months after study completion.
  14. Receipt of any investigational drug within 4 weeks before first dose, or concurrent enrollment in another interventional clinical study.
  15. Any other factors judged by the investigator that may affect study completion.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Dose Level 1: 1×10^10 Exosomes
Intratumoral injection of mechanobiologically reprogrammed macrophage-derived exosomes at a dose of 1×10^10 exosomes per injection, administered once every 2 weeks for 4 doses (3+3 dose escalation, Cohort 1).
Autologous macrophage-derived exosomes prepared from the participant's own peripheral blood monocytes. Monocytes are isolated by apheresis, differentiated into macrophages, subjected to nuclear compression via a microfluidic device to induce mechanobiological reprogramming, and then exosomes are extracted and purified by ultracentrifugation. Administered via intratumoral injection once every 2 weeks for 4 doses at a dose of 1×10^10 exosomes.
实验性的:Dose Level 2: 2.5×10^10 Exosomes
Intratumoral injection of mechanobiologically reprogrammed macrophage-derived exosomes at a dose of 2.5×10^10 exosomes per injection, administered once every 2 weeks for 4 doses (3+3 dose escalation, Cohort 2).
Autologous macrophage-derived exosomes prepared from the participant's own peripheral blood monocytes. Monocytes are isolated by apheresis, differentiated into macrophages, subjected to nuclear compression via a microfluidic device to induce mechanobiological reprogramming, and then exosomes are extracted and purified by ultracentrifugation. Administered via intratumoral injection once every 2 weeks for 4 doses at a dose of 2.5×10^10 exosomes.
实验性的:Dose Level 3: 5×10^10 Exosomes
Intratumoral injection of mechanobiologically reprogrammed macrophage-derived exosomes at a dose of 5×10^10 exosomes per injection, administered once every 2 weeks for 4 doses (3+3 dose escalation, Cohort 3).
Autologous macrophage-derived exosomes prepared from the participant's own peripheral blood monocytes. Monocytes are isolated by apheresis, differentiated into macrophages, subjected to nuclear compression via a microfluidic device to induce mechanobiological reprogramming, and then exosomes are extracted and purified by ultracentrifugation. Administered via intratumoral injection once every 2 weeks for 4 doses at a dose of 5×10^10 exosomes.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of Dose-Limiting Toxicity (DLT)
大体时间:From first administration through Day 28 post-administration (approximately 4 weeks)
DLT is defined as treatment-related adverse events graded per NCI CTCAE v5.0 occurring during the DLT observation period, including grade ≥4 hematologic toxicity or grade ≥3 non-hematologic toxicity (with exceptions).
From first administration through Day 28 post-administration (approximately 4 weeks)

次要结果测量

结果测量
措施说明
大体时间
Objective Response Rate (ORR)
大体时间:Up to 12 months
Proportion of participants achieving complete response (CR) or partial response (PR) per RECIST v1.1 criteria
Up to 12 months
Progression-Free Survival (PFS)
大体时间:Up to 24 months
Time from first administration to disease progression or death from any cause, assessed per RECIST v1.1
Up to 24 months
Overall Survival (OS)
大体时间:Up to 24 months
Time from first administration to death from any cause
Up to 24 months
Incidence of Treatment-Emergent Adverse Events (TEAEs)
大体时间:Up to 6 months
Number and severity of adverse events graded per NCI CTCAE v5.0
Up to 6 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年5月10日

初级完成 (估计的)

2027年3月1日

研究完成 (估计的)

2028年5月1日

研究注册日期

首次提交

2026年4月26日

首先提交符合 QC 标准的

2026年4月26日

首次发布 (实际的)

2026年5月4日

研究记录更新

最后更新发布 (实际的)

2026年5月11日

上次提交的符合 QC 标准的更新

2026年5月6日

最后验证

2026年4月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • 2026-796

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅